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Abstract
Objective: Psoriatic arthritis (PsA) and scleroderma (SSc) are chronic rheumatic disorders with detrimental effects
on health-related quality of life. Our objective was to assess health values (utilities) from the general public for
health states common to people with PsA and SSc for economic evaluations.
Methods: Adult subjects from the general population in a Midwestern city (N = 218) completed the SF-12 Health
Survey and computer-assisted 0-100 rating scale (RS), time trade-off (TTO, range: 0.0-1.0) and standard gamble (SG,
range: 0.0-1.0) utility assessments for several hypothetical PsA and SSc health states.
Results: Subjects included 135 (62%) females, 143 (66%) Caucasians, and 62 (28%) African-Americans. The mean
(SD) scores for the SF-12 Physical Component Summary scale were 52.9 (8.3) and for the SF-12 Mental Component
Summary scale were 49.0 (9.1), close to population norms. The mean RS, TTO, and SG scores for PsA health states
varied with severity, ranging from 20.2 to 63.7 (14.4-20.3) for the RS 0.29 to 0.78 (0.24-0.31) for the TTO, and 0.48 to
0.82 (0.24-0.34) for the SG. The mean RS, TTO, and SG scores for SSc health states were 25.3-69.7 (15.2-16.3) for the
RS, 0.36-0.80 (0.25-0.31) for the TTO, and 0.50-0.81 (0.26-0.32) for the SG, depending on disease severity.
Conclusion: Health utilities for PsA and SSc health states as assessed from the general public reflect the severity of
the diseases. These descriptive findings could have implications regarding comparative effectiveness research for
tests and treatments for PsA and SSc.
Introduction
Skin and joint disorders can substantially impact physical
and psychological function. Psoriatic arthritis (PsA) and
scleroderma (SSc) are 2 such disorders having varying
degrees of severity and functional impairment, potentially
resulting in long-term work disability [1,2]. Although
incidence and prevalence rates vary in the literature, PsA
is thought to affect 200-1000 per million people, and SSc
300-700 people per million [3,4]. PsA is characterized by
a specific pattern of inflammatory joint disease, negative
rheumatoid factor serology, and hyperkeratotic plaques
that usually occur on the elbows, knees, and scalp. People
with PsA often have extra-articular inflammatory features
involving nail beds, entheses, and the uveal tract.
Although there is no relationship between the degree of
skin involvement and the severity of psoriatic arthritis,
both aspects of this disease have important implications
for its sufferers [5]. Similarly, people with SSc have vary-
ing degrees of both skin hardening and systemic involve-
ment, which may include arthritis. SSc is categorized as
limited SSc or diffuse SSc, depending on the extent of
skin involvement [6]. Patients with limited SSc generally
h a v eam o r ef a v o r a b l eo u t c o m e ,w i t ha5 - y e a rs u r v i v a l
rate as high as 86% [7]. Diffuse SSc is characterized by
rapid skin thickening and potentially severe pulmonary,
cardiac, renal, and gastrointestinal involvement occurring
in the first 3-5 years of the disease [6].
Despite disparate prognoses due to their systemic
effects, both PsA and SSc have a detrimental effect on
patient’s health-related quality of life (HRQoL) [8,9].
There are 2 standard approaches to assessing HRQoL:
1) the health status approach, which describes function-
ing and the impact of illness on specific domains of
health (e.g., physical functioning and pain, as captured
by measures such as the SF-12 Health Survey), and 2)
the value/preference/utility approach, which assesses the
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pants take hypothetical risks or make hypothetical trade-
offs among health states and summarizes HRQoL in a
single number [10-12]. Health value measures include
the time tradeoff (TTO) and standard gamble (SG). The
TTO ascertains one’s willingness to sacrifice longevity
for better health. The SG ascertains one’s willingness to
undergo risky treatments in order to improve health.
Health values can be assessed either directly from sub-
jects or indirectly through health state classification sys-
tems, which map community-derived utilities onto
subjects’ health states. Health utilities most often serve
as quality-of-life weights for calculating quality-adjusted
life years (QALYs) in decision and cost-effectiveness
analyses [13].
Utilities have been assessed directly both from patients
with psoriasis and SSc [2,14]. The U.S. Public Health Ser-
vice Panel on Cost-Effectiveness in Health and Medicine,
however, has recommended using utilities derived from
the general public, rather than from patients, for cost-
effectiveness analyses [15]. Our objective was to assess
utilities from the general public for health states common
to people with PsA and SSc in order to provide “off-the-
shelf” community quality-of-life weights for future deci-
sion and cost-effectiveness analyses involving diagnostic
strategies or treatments for PsA and SSc. By excluding
patients with these conditions, the utility of these health
states from a societal standpoint could be assessed.
Methods
Study Subjects
We recruited 218 subjects age 18 years or older from
Cincinnati, Ohio through flyers, posters posted at the
University of Cincinnati and local grocery stores, and
advertisements in local newspapers. Because patients
with inflammatory arthritides suffer symptoms of joint
pain and swelling and have difficulty in carrying out
avocational activities and activities of daily living, and
because the purpose of the project was to assess health
values from the societal perspective (that is, from people
by-and-large not familiar with the health states under
study), we chose not to include people who had inflam-
matory arthritis. Thus, all subjects who did not have a
history of inflammatory arthritides such as PsA, SSc, or
rheumatoid arthritis (patients with osteoarthritis and
fibromyalgia were allowed to participate), and who were
able to read English were eligible. The protocol was
approved by the University of Cincinnati Institutional
Review Board and all subjects provided informed con-
sent. Subjects received $30 gift cards for participating.
Questionnaires
All subjects completed the questionnaires in face-to-face
structured interview. Subjects first answered demographic
questions about their age, sex, ethnicity, marital status,
household income, and highest level of education attained.
Participants’ health status was assessed by using the SF-12
[16-18], a generic health status measure consisting of 12
items assessing 8 domains or subscales [16]. The 8 SF-12
subscales can be summarized into a Physical Component
Summary (PCS) and a Mental Component Summary
(MCS) score. Summary scores are normed to the U.S. gen-
eral population, where the mean score is 50 and the stan-
dard deviation is 10. We used version 2 of the SF-12 and a
standard (4-week) recall period.
Description of Health States
Each subject was given a brief description of PsA and SSc
health states (Appendix) and asked to imagine how it
would be to spend the rest of their life in that health
state. We developed a total of 3 PsA and 5 SSc health
states by using health state attributes from the Quality of
Well-Being Self-Administered (QWB-SA) scale, a health
state classification measure [19], supplemented by our
own descriptions of skin and lung disease. The QWB-SA
includes an exhaustive set of health outcome states and
has been used in a variety of studies. Normative data on
the QWB-SA are available [20-22]. The 3 PsA health
states were: mild PsA, moderate PsA, and severe PsA.
Severity was categorized by ability to perform major
activities and self-care activities; the degree of skin invol-
vement with psoriasis was not varied among PsA states.
The 5 SSc health states were: mild SSc, moderate SSc,
moderate SSc with lung disease, severe SSc, and severe
SSc with lung disease. We specifically included lung dis-
ease in 2 of the SSc health states because lung disease
(due either to pulmonary hypertension, interstitial lung
disease, or both) is the leading cause of death in patients
with SSc and because new therapies for lung disease have
been approved recently or are being studied in clinical
trials. We chose not to differentiate between pulmonary
hypertension and interstitial lung disease for the SSc
health states, as breathlessness is a common symptom for
both conditions. Each subject rated 3 of the 5 randomly
selected hypothetical SSc states, grouped according to
the type of SSc (limited versus diffuse). In other words,
participants valued 3 limited SSc disease health states or
3 diffuse SSc disease health states.
Utility Measures
Health utilities were elicited by a trained interviewer
(S.G.) using U-Maker, a computer-assisted utility assess-
ment software package [23]. Details of the assessment
procedure have been published previously [2]. Briefly,
subjects first rated the health states on a health rating
scale (RS), which was presented as a “feeling thermo-
meter” with scores ranging from 0 (dead) to 100 (perfect
health). Next, participants completed a TTO exercise,
which was represented graphically as a choice between 2
horizontal bars, 1 representing the full life expectancy in
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the other representing a given number of years (less
than or equal to the life expectancy) in perfect health
followed by death [23]. Based on the age of the subject,
U-Maker utilized the life expectancy reported in U.S.
life tables, rounding the life expectancy to the nearest
5 years [24]. The number of years in perfect health vs.
in the PsA or SSc health state was varied in a “bisection”
fashion until the patient no longer had a clear prefer-
ence between living in the given health state or living
the given amount of time in perfect health [25]. The
TTO score was calculated by dividing the number of
years of perfect health at the indifference point by the
full life expectancy.
The final utility task was the SG. Participants were
shown two circles: one was labeled with the PsA or SSc
health state in question and remained the same on all of
the screens; the second circle represented “perfect heath.”
The subject was offered a choice between living the
remainder of his/her life in the given PsA or SSc health
s t a t ev s .t a k i n gag a m b l ei nw h i c ht h e2o u t c o m e sw e r e
perfect health for the remainder of life or immediate
death [26]. Initially, the second circle was displayed as a
pie chart with a 100% probability of perfect health.
Assuming the subject preferred perfect heath in that sce-
nario, the probabilities of perfect health and death in the
second circle were then varied systematically by using
bisection until the patient was indifferent between the
certainty of life in the PsA or SSc health state or the gam-
ble. The SG score was calculated by the following for-
mula: 1 - the maximum acceptable probability of death.
Comprehension and Empathy
At the end of the health utility exercise, we asked the
subjects to rate the clarity of the computer program on
a 5-point response scale: “very confusing,”“ confusing,”
“neither confusing nor clear,”“ clear,” or “very clear.” In
addition, subjects were asked if they were able to ima-
gine themselves as the person in the hypothetical health
states according to a 3-point scale: “very much,”“ a little
bit,” or “not at all.”
Statistical Analysis
Descriptive statistics for continuous variables are pre-
sented as means and standard deviations. We assessed
normality of health utility measures by using the Sha-
piro-Wilk test; the RS scores for PsA and SSc health
states were normally distributed but the TTO and SG
scores were not. Nevertheless, because mean values are
used in calculating QALYs, we present the data as
means (SDs) in the text and the tables. Categorical vari-
ables are presented as frequencies and proportions in a
contingency table format. Unadjusted comparisons for
categorical outcomes were made by using chi-square
and Fisher’s Exact tests.
Because there were no statistically significant differ-
ences in utilities for limited vs. diffuse disease within the
mild SSc, moderate SSc, severe SSc, moderate SSc with
lung disease, and severe SSc with lung disease states
(P-values ranged from 0.08 for RS scores for the severe
limited vs. severe diffuse SSc subtype to 0.90 for SG
scores for severe limited vs. severe diffuse SSc with lung
disease), we merged results for limited with diffuse by
each SSc severity category, e.g., moderate limited SSc
with moderate diffuse SSc. All analyses were performed
by using STATA software, version 9.2 (College Station,
Tex.); P < 0.05 was considered indicative of statistical
significance.
Results
Subjects’ Characteristics
The mean (SD) age of the participants was 46.0 (12.9)
years; 135 (62%) were female, 143 (66%) were Caucasian,
and 62 (28%) were African-American (Table 1). Almost
all subjects 212 (98%) graduated from high school and
155 (71%) had household incomes exceeding $25,000
per year. The mean (SD) SF-12 PCS and MCS scores
were 52.1 (8.3) and 49.0 (9.1), respectively, close to
population norms.
Health Utilities for PsA Health States
Health ratings and utilities for PsA health states were
generally inversely related to the severity of the PsA
health state. Mean (SD) RS scores ranged from 63.7
(20.3) for mild PsA to 20.2 (14.4) for severe PsA (Table 2).
Mean TTO scores ranged from 0.78 (0.24) for mild PsA to
0.29 (0.31) for severe PsA, indicating a willingness to
trade up to, on average, 22% (= [1-0.78] × 100%) of life
expectancy with mild PsA to 71% (= [1-0.29] × 100%)
of life expectancy with severe PsA in exchange for per-
fect health. Mean SG scores ranged from 0.82 (0.24) for
mild PsA to 0.48 (0.34) for severe PsA. Thus, partici-
pants were willing to accept an average risk of death as
high as 18% (= [1-0.82] × 100%) with mild PsA to 52%
(= [1-0.48] × 100%) with severe PsA for a chance at
perfect health.
Health Utilities for SSc Health States
Health ratings and utilities for SSc health states were
also inversely related to the severity of the health state.
Mean (SD) RS scores ranged from 69.7 (15.3) for mild
S S ct o2 5 . 3( 1 5 . 2 )f o rs e v e r eS S cw i t hl u n gd i s e a s e
(Table 3). Mean (SD) TTO scores ranged from 0.80
(0.25) for mild SSc to 0.36 (0.31) for severe SSc with
lung disease, indicating a willingness to forgo a mean of
20% (with mild SSc) to 64% (with severe SSc and lung
disease) of life expectancy in exchange for perfect
health. Mean SG scores ranged from 0.81 (0.26) for
mild SSc to 0.50 (0.31) for severe SSc and 0.51 (0.32)
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willing to accept an average risk of death as high as 19%
(mild SSc) to 50% (severe SSc with lung involvement)
and 51% (without lung involvement) for a chance at per-
fect health.
Comprehension and Empathy
When asked about their understanding of the computer-
assisted utility exercises, 129 (59%) of the subjects rated
it as very clear, 70 (32%) as clear, 15 (7%) as neither
clear nor confusing, 3 (2%) as confusing, and 1 (1%) as
very confusing. Of the 210 (out of 218) participants, 140
(67%) and 65 (31%) were able to empathize very much
or a little bit, respectively, with a person with the PsA
or SSc health states, and only 5 (2%) could not imagine
themselves as a person with PsA or SSc.
Discussion
PsA and SSc are chronic, often disabling diseases with a
detrimental impact on HRQoL [27,28]. Assessing health
values (utilities) - ideally from the general public - is an
essential element for economic evaluations of healthcare
interventions in these and other diseases.
Table 1 Demographics and Health Status
Age (years), mean (SD) 46.0 (12.9)
Sex
Male, N (%) 83 (38)
Female, N (%) 135 (62)
Ethnicity
Caucasian, N (%) 143 (66)
African Americans, N (%) 62 (28)
Other, N (%) 13(6)
Marital Status
Married, N (%) 96 (44)
Separated, N (%) 10 (5)
Divorced, N (%) 48 (22)
Widowed, N (%) 11 (5)
Single, N (%) 52 (24)
Education
Did not finish high school, N (%) 6 (2)
High school graduate, N (%) 43 (20)
Started but did not complete college, N (%) 70 (32)
College graduate, N (%) 59 (27)
Post graduate, N (%) 38 (18)
Annual Income
< $12,000, N (%) 34 (16)
$12,000-25,000, N (%) 29 (13)
$25,000-50,000, N (%) 67 (31)
$50,000-75,000, N (%) 46 (21)
> $75,000, N (%) 31 (14)
Preferred not to say 11 (5)
Health Status
SF-12 Physical Component Summary, mean (SD) 52.1 (8.3)
SF-12 Mental Component Summary, mean (SD) 49.0 (9.1)
Health Assessment Questionnaire-Disability Index, mean (SD) 0.12 (0.30)
Table 2 Psoriatic Arthritis Utilities
Health State Number of respondents Mean SD
Mild PsA
RS 70 63.7 20.3
TTO 70 0.78 0.24
SG 70 0.82 0.24
Moderate PsA
RS 78 45.7 16.9
TTO 78 0.58 0.31
SG 78 0.67 0.30
Severe PsA
RS 66 20.2 14.4
TTO 66 0.29 0.31
SG 66 0.48 0.34
SD: standard deviation; PsA: psoriatic arthritis; RS: rating scale (range: 0-100);
TTO: time tradeoff (range: 0.0-1.0); SG: standard gamble (range: 0.0-1.0).
Table 3 Scleroderma Utilities
Health State Number of
respondents
Mean SD
Mild SSc
RS 94 69.7 15.3
TTO 94 0.80 0.25
SG 94 0.81 0.26
Moderate SSc
RS 172 54.9 15.8
TTO 172 0.68 0.28
SG 172 0.76 0.27
Moderate SSc with lung
involvement
RS 177 45.3 15.5
TTO 177 0.59 0.3
SG 177 0.68 0.28
Severe SSc
RS 120 30 16.3
TTO 120 0.37 0.29
SG 120 0.50 0.31
Severe SSc with lung
involvement
RS 90 25.3 15.2
TTO 90 0.36 0.31
SG 90 0.51 0.32
SD: standard deviation; PsA: psoriatic arthritis; RS: rating scale (range: 0-100);
TTO: time tradeoff (range: 0.0-1.0); SG: standard gamble (range: 0.0-1.0).
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ties from the general public. First, patients with a parti-
cular disease can fill out a health state classification
instrument that uses population-assigned weights to cal-
culate utility scores for particular health states. A variety
of measures are available for this purpose, including the
EQ-5 D, the QWB-SA, the Health Utilities Index, and
the SF-6 D [16,29-32]. The SF-6 D, which is derived
from the SF-36 Health Survey, is a health state classifi-
cation instrument that uses population weights assessed
in the U.K. Using data from two different studies, we
analyzed SF-6 D scores in patients with either limited or
diffuse SSc of varying severity [8]. The mean (SD) SF-6
D scores in the two studies were 0.61 (0.12) and 0.64
(0.13) on a scale ranging from 0.29 to 1.00. Neither
study assessed the severity of patients’ SSc.
The second method is to ask people from the general
public directly to value health states common to a parti-
cular disease. The advantage of this method over the
health state classification measurement method is that
specific aspects of the disease can be described in various
ways (e.g., with pictures or videos) beyond simple brief
written descriptions available in a generic health status
measure [33,34]. To obtain community utilities for PsA
and SSc, we interviewed 218 participants in a mid-size
city in the U.S. The proportion of Caucasians (66%) in
our sample is representative of the 2005 U.S. census and
the proportion of African-Americans (28%) is representa-
tive of the city in which the study took place. The health
status of our participants, as captured by the SF-12, was
similar to that of the U.S. general population [16,35].
The utility approach explicitly acknowledges that pre-
ferences are used to express the relative importance of
various health outcomes [21]. Understanding the con-
cepts of the SG and TTO may be difficult for some sub-
jects. To assess that, we asked our participants about
their understanding of the health value assessment exer-
cise; 91% rated it as clear or very clear. In addition, 98%
of participants were able to empathize with the persons
described in the PsA and SSc health states. Both of
these findings lend confidence to our results. Further-
more, the health utility scores for mild, moderate and
severe PsA and SSc support the construct validity of the
utility measures in that more severe health states were
assigned lower utilities than were less severe health
states. In addition, as described in the literature pre-
viously, TTO and SG scores were generally relatively
higher than RS scores, as the RS does not involve trade-
offs against an external metric such as time or risk of
death. Our findings are consistent with previously pub-
lished data that suggest that utility values derived using
the SG are higher than those using the TTO for more
severe health states, whereas the reverse may be true for
less severe health states [36-38].
Several of our findings warrant particular attention.
First, subjects assigned similar disutility to mild SSc and
PsA health states, but moderate and severe PsA was
assigned a greater disutility (lower utility) than moderate
and severe SSc with or without lung involvement. This
finding may be due to the public’s perception that hav-
ing thickened skin (from SSc) is more acceptable than
having erythematous, pruritic scaly skin lesions (from
PsA). Alternatively, it is possible that participants did
not fully understand the full spectrum of differences
between the two diseases, especially as related to mor-
tality. This also may be reflective of the relatively young
population of respondents, or their relatively low educa-
tion and/or socioeconomic status.
Our data corroborate previous research showing that
the general public assigns greater disutility to hypotheti-
cal health states in most, but not all, circumstances than
do patients experiencing those health states [39]. When
health utilities were assessed in 107 patients with SSc of
varying severity, the mean RS, TTO, and SG scores
were 64.3, 0.76, and 0.74, respectively [2], scores that
fell in the least severe SSc categories in our study.
Health utilities have also been assessed in patients with
psoriasis but without arthritis [14]. In those patients, the
RS, TTO, and SG correlated inversely with extent of
skin involvement. Specifically, the median RS score was
0.76 for patients having less than 10% of their skin sur-
face involved vs. 0.34 for those having more than 30%
skin involvement. Corresponding median TTO and SG
values were 0.99 for both measures (< 10% of skin
involved) vs. 0.75 for both measures (> 30% of skin
involved). Although patient-derived utilities are valuable
for decision making involving individual patients, for
cost-effectiveness analyses, the U.S. Public Health Ser-
vice Panel on Cost-Effectiveness in Health and Medicine
has recommended using utilities assessed from the gen-
eral public [15]. Although the general public tends to
underestimate utilities of patients with a given condi-
tion, the Panel reasoned that community utilities for
hypothetical health states represent the public’s interest
better [40,41]. Also, members of the general public are
potential future patients [42].
We had hypothesized that the general public would
assign a lower utility to diffuse SSc, which manifests as
greater skin thickening compared with limited SSc, for
otherwise similar health states. Surprisingly, this was not
the case. In other words, to the general public, the
extent of skin thickening does not significantly affect the
value of SSc health states. This finding may due to the
way the health states were described or to limited power
to detect differences in utilities for limited vs. diffuse
SSc; alternatively, when assigning utilities, subjects may
have focused more on ability to perform avocational and
day-to-day activities rather than the extent of skin
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necessity are limited in the number of attributes they
cover. Because we based our health state descriptions on
the QWB-SA, we did not include additional clinical
manifestations of PsA and SSc. It is possible that had
we described additional aspects of severe SSc (e.g., finger
contractures, painful ulcers, and painful calcinosis), then
the utility for severe SSc might have been lower, perhaps
even lower than the utility for PsA. Capturing those
manifestations may have elucidated differences in utili-
ties related to extraarticular features of PsA and to
extent of involvement of SSc, but also may have gener-
ated too many health states for the subjects to be able
to process. We also did not include prognostic informa-
tion in describing the health states for diffuse vs. limited
disease and in describing the associated lung disease.
Prognostic information in the form of life expectancy is
already captured in calculating QALYs; thus, the con-
vention is to exclude prognostic information from the
health state description per se so as to avoid double
counting [43]. Still, although diffuse SSc is more severe
than limited SSc, in a previous study of patients with
SSc we found that SG scores were actually higher
among patients with the diffuse subtype (mean score
0.79 vs. 0.69 for patients with limited SSc) and that
TTO scores were similar (0.76 for diffuse SSc and 0.77
for limited SSc) in the two groups [2].
Our study had several limitations. Participants were
not selected randomly - rather, they were a convenience
sample of respondents to newspaper ads and posters in
one city. Thus, it is unlikely that the sample is truly
representative of the U.S. population, especially given
our low proportion of Hispanic patients. Nationally, His-
panics represent 14% of the U.S. population [44].
Although health utilities generally don’td i f f e rb ye t h n i -
city, further research is necessary [45]. Second, we
sought to recruit subjects who had not experienced
symptoms of inflammatory arthritis. By excluding
patients with SSc, PsA, and other inflammatory arthri-
tides from the utility assessment exercise, the results
m a yb es l i g h t l yn o n - r e p r e s e n t a t i v eo ft h eg e n e r a lp o p u -
lation. We believe that any such bias is minimal, given
that with a sample size of 218, one would only expect to
have 3-4 patients with these conditions [46,47].
Conclusion
These limitations notwithstanding, this study provides
community-based quality-of-life weights for PsA and
SSc health states. Understanding and taking into
account these values is important for determining
treatment strategies. As such, these findings could
have implications regarding comparative effectiveness
research.
Appendix Health State Descriptions
Mild Psoriatic Arthritis
Imagine that you:
￿ Travel in a car or by public transportation without
difficulty.
￿ Do not have problems walking around.
￿ Independently perform all major activities (e.g.,
working, moderate exercise or household chores).
￿ Independently perform all self-care activities (e.g.,
eating, dressing and bathing).
However, sometimes your hands and feet are painful,
swollen and stiff when you do these things.
Also, you have a health condition that has caused:
￿ Raised, reddish skin covered by silvery-white scale
on the elbows, knees, lower back, and scalp.
￿ Your skin to itch often.
￿ Your skin to sometimes crack and bleed.
Moderate Psoriatic Arthritis
Imagine that you:
￿ Travel in a car or by public transportation with
some difficulty.
￿ Have problems walking around and sometimes
need to use a cane.
￿ Can not independently perform all major activities
(e.g., working, moderate exercise or household
chores).
￿ Can independently perform all self-care activities
(e.g., eating, dressing and bathing).
However, often your hands and feet are painful, swol-
len and stiff.
Also, you have a health condition that has caused:
￿ Raised, reddish skin covered by silvery-white scale
on the elbows, knees, lower back, and scalp.
￿ Your skin to itch often.
￿ Your skin to often crack and bleed.
Severe Psoriatic Arthritis
Imagine that you:
￿ Travel in a car or by public transportation with
much difficulty.
￿ Have problems walking around and sometimes
need to use a cane.
￿ Can not Independently perform all major activities
(e.g., working, moderate exercise or household
chores).
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ities (e.g., eating, dressing and bathing).
However, your hands and feet are constantly very
painful, swollen and stiff.
Also, you have a health condition that has caused:
￿ Raised, reddish skin covered by silvery-white scale
on the elbows, knees, lower back, and scalp.
￿ Your skin to itch often.
￿ Your skin to often crack and bleed.
￿ Discomfort that may keep you up at night.
Mild Limited Scleroderma
Imagine that you:
￿ Travel in a car or by public transportation without
difficulty.
￿ Do not have problems walking around.
￿ Independently perform all major activities (e.g.,
working, moderate exercise or household chores).
￿ Independently perform all self-care activities (e.g.,
eating, dressing and bathing).
However, sometimes your JOINTS are painful, swollen
and stiff.
Also, you have a health condition that has:
￿ Caused thickening and hardening of your skin.
￿ Left you with slight scarring on your face, hands,
arms, and legs.
Moderate Limited Scleroderma
Imagine that you:
￿ Travel in a car or by public transportation with
some difficulty.
￿ Have problems walking around and sometimes
need to use a cane.
￿ Can not independently perform all major activities
(e.g., working, moderate exercise or household
chores).
￿ Can independently perform all self-care activities
(e.g., eating, dressing and bathing).
However, often your JOINTS are painful, swollen and
stiff.
Also, you have a health condition that has:
￿ Caused thickening and hardening of your skin.
￿ Left you with some scarring on your face, hands,
arms, and legs.
Moderate Limited Scleroderma with Lung Disease
Imagine that you:
￿ Travel in a car or by public transportation with
some difficulty.
￿ Have shortness of breath which causes some pro-
blems in walking around (you need to stop and
catch your breath sometimes).
￿ Can not Independently perform all major activities
(e.g., working, moderate exercise or household
chores).
￿ Can Independently perform all self-care activities
(e.g., eating, dressing and bathing).
However, often your JOINTS are painful, swollen and
stiff.
Also, you have a health condition that has:
￿ Caused thickening and hardening of your skin.
￿ Left you with some scarring on your face, hands,
arms, and legs.
Severe Limited Scleroderma
Imagine that you:
￿ Travel in a car or by public transportation with
much difficulty.
￿ Have problems walking around and sometimes
need to use a cane.
￿ Can not Independently perform all major activities
(e.g., working, moderate exercise or household
chores).
￿ Can not independently perform all self-care activ-
ities (e.g., eating, dressing and bathing).
However, your JOINTS are constantly very painful,
swollen and stiff.
Also, you have a health condition that has:
￿ Caused thickening and hardening of your skin.
￿ Left you with some scarring on your face, hands,
arms, and legs.
Severe Limited Scleroderma with Lung Disease
Imagine that you:
￿ Travel in a car or by public transportation with
much difficulty.
￿ Have shortness of Breath which causes some pro-
blems in walking around (you need to stop and
catch your breath and use a cane sometimes).
￿ Can not Independently perform all major activities
(e.g., working, moderate exercise or household chores).
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Page 7 of 9￿ Can not independently perform all self-care activ-
ities (e.g., eating, dressing and bathing).
Your JOINTS are constantly very painful, swollen and
stiff.
Also, you have a health condition that has:
￿ Caused thickening and hardening of your skin.
￿ Left you with some scarring on your face, hands,
arms, and legs.
Diffuse scleroderma health state descriptions were the
same as above except for the statement: “Health condi-
tion has left you with significant scarring on large por-
tions of your face, hands, arms, and legs.”
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